meta
|
evidence
oncology
Living systematic review and meta-analysis
refractory classic Hodgkin lymphoma (R/R cHL)
R/R cHL - second line or more (L2)
1
colorectal cancer (CRC)
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
atezolizumab plus cometinib
pembrolizumab based treatment
pembrolizumab alone
Immune checkpoint association
durvalumab plus tremelimumab
versus all
vs chemotherapy
vs Standard of Care (SoC)
vs non active control
vs BSC
vs VEGF(R) inhibitor
vs regorafenib
All patients
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
deaths (OS)
objective responses (ORR)
objective responses (ORR) (extension)
progression or deaths (PFS)
AE (grade 3-4)
AE leading to death (grade 5)
AE leading to treatment discontinuation (any grade)
SAE (any grade)
deaths (OS)
mCRC - 1st line (L1)
metastatic/advanced - colorectal cancer (mCRC)
mCRC - 1st line (L1)
mCRC - 2nd line (L2)
metastatic/advanced - colorectal cancer (mCRC)
mCRC - 2nd line (L2)
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open